vTv Graps Logo.png
vTv Therapeutics Announces 2021 Third Quarter Financial Results and Provides Corporate Update
November 09, 2021 08:30 ET | vTv Therapeutics Inc.
HIGH POINT, N.C., Nov. 09, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third quarter ended September 30, 2021, and provided an update on the...
SymbioCellTech Demonstrates Preclinical Efficacy of Proprietary and Novel Human Neo-Islets™ Technology in STZ-Diabetic NOD-SCID Mice
October 28, 2021 14:30 ET | SymbioCellTech, LLC
SALT LAKE CITY, Oct. 28, 2021 (GLOBE NEWSWIRE) -- SymbioCellTech (SCT) announced today the publication of a paper demonstrating the potency and efficacy of its innovative and proprietary human...
vTv Graps Logo.png
vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with TTP399 during Acute Insulin Withdrawal in Patients with Type 1 Diabetes
October 12, 2021 07:30 ET | vTv Therapeutics Inc.
Study achieved primary endpoint of non-inferiority on measurement of key blood ketone levels Patients taking TTP399 reported no events of hypoglycemia, while four events of hypoglycemia were reported...
vTv Graps Logo.png
vTv Therapeutics Announces 2021 Second Quarter Financial Results and Provides Corporate Update
August 04, 2021 16:30 ET | vTv Therapeutics Inc.
HIGH POINT, N.C., Aug. 04, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter ended June 30, 2021, and provided an update on the...
vTv Graps Logo.png
vTv Therapeutics Announces 2021 First Quarter Financial Results and Provides Corporate Update
May 05, 2021 16:10 ET | vTv Therapeutics Inc.
Awarded Breakthrough Therapy designation for TTP399 for the treatment of type 1 diabetes Initiated two phase 1 clinical studies, mechanistic study of TTP399 and multiple ascending dose study of...
vTv Graps Logo.png
vTv Therapeutics Receives FDA Breakthrough Therapy Designation for TTP399 for the Treatment of Type 1 Diabetes
April 13, 2021 07:30 ET | vTv Therapeutics Inc.
HIGH POINT, N.C., April 13, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for...
vTv Graps Logo.png
TTP399 SimpliciT-1 Study Results to be presented at a scientific symposium in celebration of the 100th anniversary of the discovery of insulin
April 12, 2021 16:30 ET | vTv Therapeutics Inc.
HIGH POINT, N.C., April 12, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for...
vTv Graps Logo.png
vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using TTP399
March 23, 2021 07:30 ET | vTv Therapeutics Inc.
HIGH POINT, N.C., March 23, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) announced today that the U.S. Patent and Trademark Office has issued a patent with claims protecting methods...
vTv Graps Logo.png
vTv Therapeutics Announces Initiation of Study Evaluating TTP399’s Potential to Reduce Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes
March 18, 2021 16:05 ET | vTv Therapeutics Inc.
HIGH POINT, N.C., March 18, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for...
Graphical Research.jpg
Digital Diabetes Management Market Size & Share 2021-2027 | North America, Europe, & APAC Industry Forecasts: Graphical Research
March 09, 2021 06:30 ET | Graphical Research
Pune, India, March 09, 2021 (GLOBE NEWSWIRE) -- The digital diabetes management market size is predicted to expand at significant CAGR during the forecast period, with the need for accurate,...